The Trump administration's Most Favored Nation (MFN) drug deals set a precedent for ad hoc negotiations. If Democrats gain power and expose these deals as lenient, it could provoke Congress to impose even more stringent, legislated price controls, ultimately harming the industry more than the current agreements.
Imposing Most Favored Nation (MFN) drug pricing on Medicaid creates a powerful, unintended disincentive for R&D investment in diseases that primarily affect this population. This could lead to companies and investors avoiding these areas, ultimately harming the patients the policy aims to help.
Eli Lilly's recent acquisition of Merida is not an isolated event but its fourth immunology-focused takeout this year. This is part of a massive $31.5 billion M&A expenditure, revealing a clear corporate strategy to build a dominant franchise in immunology alongside its other key therapeutic areas.
European venture capitalists' interest in China has evolved beyond just sourcing new deals. They now view China's clinical trial infrastructure as a strategic asset to accelerate development for their existing European portfolio companies, representing a shift from passive investment to active operational leverage.
The core concern over FDA nominee Heidi Overton is not her qualifications but a potential redefinition of the Commissioner's role. Critics fear she will act as a 'conduit' for White House ideology rather than the traditional 'heat shield' that protects agency scientists from political pressure.
The FDA's National Priority Review Voucher (CNPV) initiative accelerates drug approvals more than officially stated. Analysis reveals a significant time advantage occurs before filing acceptance, as the FDA is often not using its full 60-day submission review period, an under-the-radar benefit of the program.